NEUROLOGY 2004;62:37-40
© 2004 American Academy of Neurology
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease
William G. Ondo, MD,
Christine Hunter, RN and
Warren Moore, MD
From the Departments of Neurology (Dr. Ondo, C. Hunter) and Radiology (Dr. Moore), Baylor College of Medicine, and Nuclear Medicine Service (Dr. Moore), Texas Children’s Hospital, Houston.
Address correspondence and reprint requests to Dr. W.G. Ondo, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030; e-mail: wondo{at}bcm.tmc.edu
Background: Injections of botulinum toxin A are an effective treatment for sialorrhea in Parkinson’s disease (PD). Based on the relatively high rates of dry mouth seen with botulinum toxin B, there is reason to suspect that it may also improve sialorrhea.
Objective: To determine whether botulinum toxin B (Myobloc; Elan Pharmaceuticals, New York, NY) is a safe and effective treatment for sialorrhea in patients with PD.
Methods: Demographics, PD treatments, head posture, the Unified Parkinson’s Disease Rating Scale (UPDRS), two questionnaires regarding drooling, Visual Analogue Scale, global impressions, salivary gland imaging, and a dysphagia questionnaire were assessed in 16 PD subjects with problematic sialorrhea. Patients were then randomized to receive either botulinum toxin B (1,000 units into each parotid gland and 250 units into each submandibular gland) or a pH-matched placebo, using only anatomic landmarks. Patients returned 1 month later to undergo an identical assessment.
Results: Compared with placebo, those randomized to drug reported improvement on the Visual Analogue Scale (p < 0.001), global impressions of change (p < 0.005), Drooling Rating Scale (p < 0.05), and Drooling Severity and Frequency Scale (p < 0.001). There was no change in UPDRS, head posture, or Dysphagia Scale. Adverse events were mild and included dry mouth (three patients), worsened gait (two), diarrhea (one), and neck pain (one) in the botulinum toxin B group.
Conclusion: Anatomically guided injections of botulinum toxin B into the parotid and submandibular glands appear to effectively improve sialorrhea without compromising dysphagia in patients with PD.
Received May 2, 2003.
Accepted in final form September 8, 2003.
This article has been cited by other articles:
|
|
|
|
 
A. R. South, S. M. Somers, and M. S. Jog
Gum chewing improves swallow frequency and latency in Parkinson patients: A preliminary study
Neurology,
April 13, 2010;
74(15):
1198 - 1202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology,
May 26, 2009;
72(21_Supplement_4):
S1 - S136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Chen, D. P. Trombetta, and H. H. Fernandez
Palliative Management of Parkinson Disease: Focus on Nonmotor, Distressing Symptoms
Journal of Pharmacy Practice,
August 1, 2008;
21(4):
262 - 272.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Naumann, Y. So, C. E. Argoff, M. K. Childers, D. D. Dykstra, G. S. Gronseth, B. Jabbari, H. C. Kaufmann, B. Schurch, S. D. Silberstein, et al.
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology,
May 6, 2008;
70(19):
1707 - 1714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Turk-Gonzales and I. R. Odderson
Quantitative Reduction of Saliva Production with Botulinum Toxin Type B Injection into the Salivary Glands
Neurorehabil Neural Repair,
March 1, 2005;
19(1):
58 - 61.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Jankovic
Botulinum toxin in clinical practice
J. Neurol. Neurosurg. Psychiatry,
July 1, 2004;
75(7):
951 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
